San Francisco: neuro42, a medical technology company leading the next evolution of MRI and robotics, today announced it has appointed its lead investor, Krishna Bhupal, to its Board of Directors. Mr Bhupal is an accomplished entrepreneur and investor with a record of delivering significant shareholder value. His current involvements are in the following key industries: energy, TAJGVK hospitality, health and real estate. His current investments are focused on the deep tech space, including MedTech, and include over 12 companies at various stages of maturity.

“We are excited to have Krishna Bhupal join the neuro42 team. Krishna’s vast experience as a deep technology investor and a business leader will enable us to navigate the ever-changing global landscape. As a team, we look forward to his leadership as we drive awareness and market penetration as we scale our differentiated technology,” said Abhita Batra, Founder and Chief Strategy Officer of neuro42. “We are executing to plan, and having a successful entrepreneur like Krishna on our board gives us the advantage of an advisor and investor who supports our mission to advance MRI from screening to robotic intervention.”

Krishna said, “I am delighted to continue to be a part of neuro42’s journey to develop and market pioneering MR technologies for neurosurgical intervention, which will change the economics of accessibility, availability and accessibility of healthcare. I look forward to the Company’s next phase of growth and for it to continue to pioneer in the imaging and robotics space in America and move into the scale-up phase.”

About neuro42:

Neuro42, Inc. is a medical technology company focused on diagnostic imaging and image-guided surgical interventions of the brain. Founded by a team of successful entrepreneurs and healthcare innovators, neuro42 is developing and commercializing an intraoperative MR, AI and robot that allows easy access to MR imaging for screening, diagnosis and interventions of neurological diseases. Backed by over 40 patents, neuro42’s platform is poised to enhance patient and physician experience with its novel, easy-to-use, portable configuration.

Exit mobile version